Compare MAGN & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAGN | DBVT |
|---|---|---|
| Founded | 1864 | 2002 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 536.8M | 769.4M |
| IPO Year | N/A | N/A |
| Metric | MAGN | DBVT |
|---|---|---|
| Price | $15.15 | $19.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $16.00 | ★ $31.75 |
| AVG Volume (30 Days) | 722.4K | ★ 742.3K |
| Earning Date | 02-05-2026 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,204,000,000.00 | $5,502,000.00 |
| Revenue This Year | $5.74 | $1,768.71 |
| Revenue Next Year | $2.51 | $1,028.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 46.50 | N/A |
| 52 Week Low | $7.82 | $2.99 |
| 52 Week High | $23.19 | $26.19 |
| Indicator | MAGN | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 69.42 | 56.43 |
| Support Level | $14.52 | $18.46 |
| Resistance Level | $15.52 | $19.90 |
| Average True Range (ATR) | 0.49 | 1.58 |
| MACD | -0.12 | -0.13 |
| Stochastic Oscillator | 80.26 | 19.17 |
Magnera Corp is a supplier of a diverse portfolio of specialty materials comprised of organic and synthetic raw ingredients. The company markets its own products predominantly into stable, consumer-oriented end markets, including wipes, healthcare, adult incontinence, apparel, baby, feminine care, air filtration, and food and beverage, for disposable and durable applications. It also provides technical solutions in infrastructure markets. The company's operations are organized into two operating and reportable segments: Americas and Rest of World. It derives the majority of its revenue from the Americas, which manufactures products and components of personal care, including medical garments, wipes, dryer sheets, filtration, baby diapers and adult incontinence.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.